Insilico's 273% Revenue Surge Turns AI Biotech Profitable
HKEX-listed Insilico Medicine (3696) projects H1 2026 revenue up 273%–287% to $106.5M, swinging to a net profit of up to $39.5M. The surprise profit alert positions the AI biotech as a high-growth, cash-generating investment.